免疫蛋白酶的功能维持了KMT2A复合体驱动的白血病中的致癌基因表达.
Nuria Tubío-Santamaría1,2, Ashok Kumar Jayavelu3,4, Tina M Schnoeder1,2
1Innere Medizin C, Universitätsmedizin Greifswald, 17475, Greifswald, Germany.
Molecular cancer
|December 4, 2023
概括
针对免疫蛋白酶体,特别是PSMB8,对KMT2A重组的急性髓性白血病 (AML) 显示出希望. 将免疫蛋白酶体抑制剂与梅因抑制剂结合起来,为AML治疗提供了一个新的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 重组KMT2A (KMT2A-r) 的急性髓性白血病 (AML) 显示对色素向药物的反应,但耐药性很常见.
- 需要结合疗法来克服耐药性并提高KMT2A-rAML的治疗疗效.
- 了解功能依赖对于开发新的治疗策略至关重要.
研究的目的:
- 使用蛋白质组方法识别KMT2A-r AML中的特定漏洞.
- 研究免疫蛋白酶,特别是PSMB8在KMT2A-rAML中的作用.
- 评估单独或与男性抑制剂结合向PSMB8的治疗潜力.
主要方法:
- 蛋白质组分析以确定药物点.
- 在小鼠和人类细胞模型中,PSMB8的遗传和药理失活.
- 评估白血病细胞的增殖和正常的造血细胞功能.
- 评估BASP1转录因子水平及其对KMT2A融合点基因的影响.
- 在异种移植模型中与梅宁抑制剂的组合研究.
主要成果:
- PSMB8被确定为KMT2A-r AML中的一个特定漏洞.
- PSMB8的失活会影响白血病细胞的增殖,但不会影响正常的造血细胞.
- 免疫蛋白酶功能的破坏增加了BASP1,抑制了KMT2A融合点基因.
- 药物学PSMB8向增强了Menin抑制剂的有效性和减少了白血病负担.
- 组合疗法显示对Menin抑制剂耐药性突变的活性保持.
结论:
- 免疫蛋白酶体是KMT2A-rAML的相关治疗点.
- 选择性破坏蛋白质稳定会改变转录因子丰度和瘤网络.
- 结合免疫蛋白酶体抑制与Menin抑制,为KMT2A-rAML提供了一种新的治疗方法.
- 这一策略有望克服抗敏抑制剂耐药性的潜力.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer-Critical Genes I: Proto-oncogenes
8.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
The Proteasome
851
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
851
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


